title: [Treatment Outcomes of Advanced Gastric Cancer after Neoadjuvant Chemotherapy with S-1 and Cisplatin].
abstract: BACKGROUND
  The prognosis after neoadjuvant chemotherapy(NAC)is expected to improve in patients with resectable advanced gastric cancer who are at high risk of recurrence or those with unfavorable prognostic factors.
  
  
  METHODS
  This retrospective study examined treatment outcomes and survival of 25 patients with advanced gastric cancer who received NAC with S-1 and cisplatin(CDDP)between October 2008 and December 2015.
  
  
  RESULTS
  Among patients with clinical Stage II (4 patients)and III (21 patients)tumors, 13 had partial response(PR)and 12 had stable disease(SD). Neither complete response(CR)nor progressive disease(PD)was noted. CR of lymph node metastases was observed in 6 patients, PR in 9 patients, and SD in 7 patients. R0 resection was performed in 16 patients, R1 in 3 patients, and R2 in 6 patients. Histologic grades of primary tumors were Grade 0(1 patient), Grade 1a(16 patients), Grade 1b(5 patients), Grade 2(3 patients), and Grade 3(none). The 3-year survival rate after R0 resection was 46%, 3-year progression-free survival rate was 68%, and 3-year recurrence-free survival rate was 69%. Significant differences were observed for pathologic stages ypN0/1, 2, and 3(p=0.04), tumor down-stage(p=0.02), and overall tumor fStage I , II / III , and IV (p<0.01).
  
  
  CONCLUSIONS
  It is conceivable that R0 resection and downstaging after NAC will improve prognosis.
authors.affiliation: Dept. of General and Digestive Surgery, Kanazawa Medical University.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Funaki
authors.forename: Yoritaka
authors.initials: Y
authors.lastname: Fujii
authors.forename: Seiko
authors.initials: S
authors.lastname: Miura
authors.forename: Jun
authors.initials: J
authors.lastname: Fujita
authors.forename: Emi
authors.initials: E
authors.lastname: Morioka
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kaida
authors.forename: Toshio
authors.initials: T
authors.lastname: Ohnishi
authors.forename: Yasuto
authors.initials: Y
authors.lastname: Tomita
authors.forename: Miki
authors.initials: M
authors.lastname: Noguchi
authors.forename: Hideto
authors.initials: H
authors.lastname: Fujita
authors.forename: Shinichi
authors.initials: S
authors.lastname: Kinami
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Nakano
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Ueda
authors.forename: Takeo
authors.initials: T
authors.lastname: Kosaka
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin